|
    MRTX U.S.: Nasdaq

    Mirati Therapeutics Inc.

    Watchlist
    NEW
    Set a price target alert
    MRTXUS
    After Hours
    Last Updated: Nov 10, 2023 5:29 p.m. EST Delayed quote

    $ 56.29

    0.00 0.00%
    After Hours Volume: 2.66M
    Close Chg Chg %
    $56.29 0.52 0.93%
    Advanced Charting
    Volume: 3.61M 65 Day Avg: 2.23M
    162% vs Avg
    56.01 Day Range 56.40
    27.30 52 Week Range 101.30

    Partner Center

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    MRTX Overview

    Key Data

    • Open $56.10
    • Day Range 56.01 - 56.40
    • 52 Week Range 27.30 - 101.30
    • Market Cap $3.95B
    • Shares Outstanding 70.15M
    • Public Float 68.08M
    • Beta 1.03
    • Rev. per Employee $64.40K
    • P/E Ratio N/A
    • EPS -$12.22
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 4.62M 10/31/23
    • % of Float Shorted 6.79%
    • Average Volume 2.23M

    Performance

    5 Day
    • 0.48%
    1 Month
    • 0.61%
    3 Month
    • 45.04%
    YTD
    • 24.23%
    1 Year
    • -23.01%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 17 Full Ratings

    Recent News

    Mirati Therapeutics Gets CHMP Backing for Krazati

    Mirati Therapeutics downgraded to hold from buy at Stifel

    Mirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer Patients

    Health Care Up on Deal Activity -- Health Care Roundup

    Read full story

    These Stocks Are Moving the Most Today: Exxon, Lockheed, Northrop, Delta, Mirati, Alnylam, SolarEdge, and More

    Read full story

    Bristol Myers to Buy Mirati. Why Mirati Stock Is Falling.

    Mirati Therapeutics downgraded to neutral from buy at B. Riley

    Read full story

    Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion

    Read full story

    Shares in weapons makers Lockheed Martin, RTX surge following surprise attack on Israel and other stocks on the move

    Mirati Shares Slip Premarket on Bristol Myers Takeover

    Mirati Therapeutics Taps Aaron Ondrey as CFO to Succeed Laurie Stelzer

    Mirati Therapeutics upgraded to buy from neutral at B. Riley

    Mirati Therapeutics shares fall after lung cancer drug gets negative opinion from European regulators

    Biggest premarket movers

    Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug

    Shares of Mirati Therapeutics Inc. jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a treatment for colorectal c...

    Read full story

    Stocks Moving the Most Today: Moderna, Pinterest, Trimble, and More

    Mirati's lung cancer drug gets an accelerated approval

    Shares of Mirati Therapeutics Inc. were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people...

    Stocks on the move in premarket action

    Stocks on the move in premarket action

    Mirati Therapeutics started at neutral with $72 stock price target at B. Riley

    Fortunes Can Be Made With Bristol-Myers Squibb

    Fortunes Can Be Made With Bristol-Myers Squibb

    on GuruFocus.com

    3 No-Brainer Stocks to Buy With $500 Right Now

    on Motley Fool

    What 11 Analyst Ratings Have To Say About Mirati Therapeutics

    on Benzinga.com

    Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday

    on Benzinga.com

    Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

    on Zacks.com

    Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)

    on TipRanks.com

    Mirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial Results

    Mirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial Results

    on GuruFocus.com

    Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

    on Zacks.com

    Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

    on Zacks.com

    Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?

    on Zacks.com

    Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow

    on Zacks.com

    What's in Store for Bristol-Myers (BMY) in Q3 Earnings?

    on Zacks.com

    7 Healthcare Stocks That Can Cure a Lackluster Portfolio

    on InvestorPlace.com

    Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings

    on Benzinga.com

    Hold Rating on Mirati Therapeutics: A Comparative Analysis with Amgen and Future Prospects

    on TipRanks.com

    Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

    on Zacks.com

    The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer

    on Zacks.com

    Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

    on Zacks.com

    Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why

    on Zacks.com

    Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023

    on Benzinga.com

    Mirati Therapeutics Inc.

    Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

    Competitors

    Name Chg % Market Cap
    Johnson & Johnson -0.12% $354.47B
    Eli Lilly & Co. 1.08% $567.41B
    AbbVie Inc. 0.40% $243.71B
    Merck & Co. Inc. -0.97% $256.92B
    AstraZeneca PLC ADR -4.03% $190.74B
    AstraZeneca PLC -3.32% £156.39B
    GSK PLC -1.20% £57.62B
    Gilead Sciences Inc. 1.25% $94.6B
    Takeda Pharmaceutical Co. Ltd. -0.10% ¥6.53T
    Astellas Pharma Inc. -0.97% ¥3.22T